CJC-1295 DAC
Synthetic GHRH analog with Drug Affinity Complex for extended half-life. Provides sustained GH elevation. Often combined with Ipamorelin.
Overview
Synthetic GHRH analog with Drug Affinity Complex for extended half-life. Provides sustained GH elevation. Often combined with Ipamorelin.
Effects on Markers
Elevates GH and IGF-1 levels (sustained release), may mildly elevate fasting glucose, can cause water retention and numbness/tingling, less cortisol/prolactin impact than GHRP-6. Generally well tolerated on blood markers.
Compound Guide
Structure: Modified GRF(1-29) with a Drug Affinity Complex that binds to albumin, dramatically extending half-life from minutes to days.
Dosage:
- Standard: 2mg/week (single injection)
- Enhanced: 2mg 2x/week
- Combined with Ipamorelin: 2mg CJC-1295 DAC/week + Ipamorelin 200-300mcg 2-3x/day
Administration:
- SubQ injection, once or twice weekly due to long half-life
- Abdomen, rotate injection sites
- Take on empty stomach for optimal GH release
Key Notes:
- The DAC (Drug Affinity Complex) extends the half-life dramatically — provides continuous GH elevation rather than pulsatile release
- Creates a sustained "GH bleed" — elevated baseline GH throughout the week
- This continuous elevation is less physiological than pulsatile GH release (Tesamorelin, mod-GRF/Ipamorelin)
- Water retention and numbness/tingling in extremities are common (signs of elevated GH)
- Monitor: IGF-1, fasting glucose, HbA1c
- Some users prefer mod-GRF (CJC-1295 without DAC) for more natural pulsatile release
- Synergistic with GHRP peptides (Ipamorelin, GHRP-2, GHRP-6)
Usage History
Frequently Asked Questions
Quick Reference
Category
Peptide
Half-Life
6-8 days (with DAC)
Detection Time
N/A